Healthcare personnel knowledge, motivations, concerns and intentions regarding COVID-19 vaccines: a cross-sectional survey

Vivek Jain,1* Sarah B. Doernberg,2* Marisa Holubar,3*
Beatrice Huang,4 Carina Marquez,1 Lillian Brown,1 Luis Rubio,1
Hannah A. Sample,5 Jenna Bollyky,3 Guntas Padda,6 Daisy Valdivieso,6
Amanda Kempema,7 Christopher Leung,7 Matthew Sklar,7
Aida Julien,6 Marcus Paoletti,6 Sravya Jaladanki,6 Emerald Wan,6 Jacob Ghahremani,6 Jessica Chao,6
Yingjie Weng,8 Di Lu,8 David Glidden,6 Kevin Grumbach,4 Yvonne Maldonado,7† and George Rutherford6†

1Division of HIV, Infectious Diseases & Global Medicine, San Francisco General Hospital, University of California, San Francisco (UCSF); 2Division of Infectious Diseases, UCSF; 3Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine; 4Department of Family and Community Medicine; 5Department of Biochemistry and Biophysics; 6Department of Epidemiology and Biostatistics, UCSF; 7Division of Pediatric Infectious Diseases and 8Quantitative Sciences Unit, Stanford University School of Medicine

* Authors contributed equally to this report

Running Title: COVID-19 vaccine opinions in healthcare providers

Keywords:
COVID-19, healthcare providers, vaccine

Corresponding Author:
Vivek Jain, MD, MAS
Division of HIV, Infectious Diseases & Global Medicine
Zuckerberg San Francisco General Hospital
University of California, San Francisco (UCSF)
UCSF Box 0874
San Francisco, CA 94143-0874
Email: vivek.jain@ucsf.edu

Alternate Corresponding Author:
Sarah Doernberg, MD, MAS, FIDSA
Division of Infectious Diseases
University of California, San Francisco (UCSF)
UCSF Box 0654
San Francisco, CA 94143-0654
Email: sarah.doernberg@ucsf.edu
Key Points

Among 2,135 healthcare personnel surveyed, we found enthusiasm for COVID-19 vaccination both for individual benefit and protecting others. However, healthcare personnel rated their knowledge of COVID-19 vaccines as only moderate and harbored concerns about vaccine side effects. Education raising awareness of vaccine efficacy and side effects may help maximize vaccine uptake.
Abstract

Background: Healthcare personnel (HCP) are prioritized for earliest SARS-CoV-2 vaccine administration, yet relatively few data exist on HCP’s knowledge, motivations, concerns, and intentions regarding COVID-19 vaccines.

Methods: We conducted a cross-sectional survey Nov.16-Dec.8, 2020 among HCP enrolled in a cohort study at three Northern California medical centers serving diverse roles including COVID-19 patient care. Eligible HCP were adult (age≥18) on-site employees of the University of California, San Francisco, San Francisco General Hospital, and Stanford Healthcare. A one-time electronically-administered survey was sent to cohort HCP on November 16, 2020 and responses analyzed.

Results: Overall, among 2,448 HCP invited, 2,135 completed the COVID-19 vaccine survey (87.2% response rate). HCPs had mean age 41 years, were 73% female, and had diverse jobs including COVID-19 patient contact. Enthusiasm for vaccination was overall strong, and more HCP (1,453, 69%) said they would definitely/likely receive vaccine if formally FDA-approved versus if approved via emergency use authorization only (785, 35%). While 541 (25%) respondents wanted to be among the earliest to receive vaccine, more desired vaccination after the first round (777, 36%) or >2 months after vaccinations began (389, 18%). Top factors increasing motivation for vaccination included perceiving risk from COVID-19 to self (1,382, 65%) or to family/friends (1355, 63%). Top concerns were vaccine side effects, cited by 596 (28%), and concerns about political involvement in FDA’s approval process (249, 12%).

Conclusions: HCP were enthusiastic about COVID-19 vaccination for individual protection and protecting others, but harbored concerns about vaccine side effects. Our data may inform emerging vaccine education campaigns.
Introduction

Two mRNA vaccines against SARS-CoV-2 made by Pfizer/BioNTech [1] and Moderna [2] recently showed 95% and 94.1% efficacy and received U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) in December 2020. The Centers for Disease Control (CDC) Advisory Committee on Immunization Practices endorsed both COVID-19 vaccines [3, 4] and designated healthcare personnel as top priority for immediate vaccination. [5] However, relatively little is known about healthcare personnel’s knowledge, attitudes, motivations and intentions surrounding COVID-19 vaccines. To address these questions and inform emerging vaccine education campaigns, we surveyed frontline healthcare personnel at three academic medical centers about COVID-19 vaccines.

Methods

Study setting: The CHART Study (COVID-19 Healthcare Worker Antibody and RT-PCR Study) is a longitudinal cohort study of adult (age≥18) healthcare personnel working at the University of California, San Francisco (UCSF), Zuckerberg San Francisco General Hospital, and Stanford Health Care during the pandemic. Cohort members enrolled from July-November 2020 at all three centers. Persons from all job types were eligible to enroll, regardless of whether they directly cared for patients with COVID-19. Exclusion criteria included not working on site during the pandemic or planning to end employment in <6 months.

Survey: Participants were sent an electronic link to a web-based eight-question web-based survey via REDCap (Research Electronic Data Capture) about COVID-19 knowledge, motivations, concerns, and intentions on November 18, 2020. Participants completed surveys over three weeks. Data were analyzed on December 8, 2020.

Analysis: Proportions of respondents answering each question were tabulated and analyzed.
Ethics: The CHART Study and the COVID-19 vaccine survey were approved by the UCSF Committee on Human Subjects Research and the Stanford University School of Medicine Panel on Human Subjects in Medical Research.

Patient Consent Statement: All participants provided informed written consent for participation.

Results

Of 2,135/2,448 (87.2%) healthcare personnel completed the COVID-19 vaccine survey. Healthcare personnel had mean age of 41.4 years and were 73% female (Table 1). Overall, 839 (39.3%) were registered nurses, and 478 (22.4%) were physicians. Work locations included intensive care units (11.5%), hospital wards (17.8%), and emergency department/urgent care (7.9%). In total, 574 (26.9%) provided direct patient care involving airway intubation/suctioning, and 1,050 (49.2%) provided direct patient care not involving airway procedures.

On a 5-point graduated scale, only 411/2,135 (19%) respondents reported being highly informed (3%) or well informed (16%) about COVID-19 vaccine candidates (Fig.1). Most reported an average (30%) or somewhat informed (36%) level of knowledge, and 314 (16%) reported they were not informed at all.

When asked about intention to receive a COVID-19 vaccine with formal FDA approval, 1,453 (69%) indicated they would definitely (35%) or likely (34%) receive it. Only 10% indicated they were unlikely to or definitely would not receive it. When asked about receiving a COVID-19 vaccine that only had FDA emergency use authorization, but lacked formal FDA approval, only 36% said they would definitely (11%) or likely (25%) receive it; this was 48% lower than if vaccine was fully FDA-approved.

When asked about vaccine timing, 541 (25%) indicated desire to be among the first to receive it, while 36% desired receiving it early, but not in the first round. Conversely, 18% indicated desire to wait >2 months before vaccination, and only 5% said they were not planning to receive it at all.
In total, 573/2,135 (27%) of healthcare personnel indicated they wanted a COVID-19 vaccine to have near 100% efficacy before receiving it, and 981 (46%) desired 80% vaccine efficacy. Only 448 (21%) said they would receive a vaccine having 60% efficacy. To understand healthcare personnel’s prior vaccination patterns, we queried their status of influenza vaccination in the same winter season. The vast majority of respondents (2088 [98%]) reported already receiving influenza vaccine this season.

Finally, we queried what factors would increase motivation and desire for a COVID-19 vaccine. The highest-ranked factor was a perception of self-risk of risk of acquiring COVID-19 cited by 1,382 (65%) respondents as a strong or somewhat strong factor (Fig.2, Panel A), though only 30% perceived a high personal medical risk of COVID-19 complications. Perception of placing family members and friends at some risk of COVID-19 was cited by 1,355 (63%) as a strong or somewhat strong factor. Factors cited as mildly or not at all increasing desire for COVID-19 vaccination included a self-perception of high medical risk and COVID-19 complications (1,491, 70%), living with individuals at high risk of acquiring COVID-19 (1,442, 67%), or living with individuals at higher risk of COVID-19 complications (1,442, 67%).

Top-ranked factors making healthcare personnel not want to receive COVID-19 vaccination included worry about potential side effects (596, 28%), political involvement in FDA vaccine evaluation and approval processes of vaccine evaluation and approval (454, 21%), and uncertainty about vaccine efficacy (249, 12%, [Fig.2, Panel B]). Distrust of pharmaceutical companies was only cited by 339 (16%) as a strong or somewhat strong factor decreasing desire for COVID-19 vaccination. Distrust of pharmaceutical companies was only cited by 339 (16%) as a strong or somewhat strong factor influencing them against wanting a COVID-19 vaccine.

**Discussion**

On the eve of regulatory approvals of the first two COVID-19 vaccines,[6, 7] we surveyed over 2,000 healthcare personnel at three large Northern California medical centers and found overall very high enthusiasm and intention to be vaccinated for the protective benefits and secondary benefits to family and friends. However, we
also found concerns about vaccine side effects and efficacy, and about political influence on regulatory approval processes. To our knowledge, this is one of the largest surveys to date of U.S. healthcare personnel on knowledge and intentions regarding COVID-19 vaccines.

Our findings may help inform public education campaigns directed at healthcare personnel and the general public to promote uptake of COVID-19 vaccines. Additionally, since many individuals will seek information about COVID-19 vaccines from healthcare providers, our data may also help reinforce reasons for vaccination and enable healthcare personnel to respond to concerns and provide reassurance where possible.[8]

Our findings on motivations for and concerns about vaccination are similar to a September survey in which Los Angeles healthcare personnel cited self-protection and preservation of community health as key reasons for COVID-19 vaccination and expressed confidence in vaccine safety and efficacy.[9] However, in that study 67% of healthcare workers cited an intention to delay COVID-19 vaccination initially, and 47% expressed reluctance about participating in a COVID-19 vaccine clinical trial, far higher than we found in our more recent survey. Likewise, in our study, we found more enthusiasm for vaccination than in a recent study conducted at SUNY Syracuse in November 2020 in which only 58% of the healthcare personnel surveyed expressed any intent to be vaccinated. [10] Notably, our population had a higher degree of racial and ethnic diversity; 53% of our study cohort are white compared with 85% of the SUNY Syracuse population surveyed. Among French healthcare personnel surveyed even earlier in the pandemic in March-July 2020, 77% intended to receive COVID-19 vaccine, motivated primarily by self-risk. [11] Notably, only 57% of respondents reported receiving influenza vaccine, far lower than the nearly 100% rate we observed.

Healthcare personnel's motivations for COVID-19 vaccination mirror those seen in the general population. In a survey of U.S. adults in April 2020, 58% reported intent to receive a COVID-19 vaccine. [12] Factors predicting vaccine hesitancy included younger age, African American race, and not having influenza vaccine in the prior
year. Notably, the surveys of the U.S. general public [12] and French healthcare personnel [11] were both done early in the pandemic, long before recent reports on vaccine efficacy and safety.

Our study contains certain limitations: it was conducted rapidly from mid-November to early December 2020 in a dynamic environment of emerging data on COVID-19 vaccines. Efficacy and side effect data on the Pfizer-BioNTech [1]and Moderna [2] vaccines were made public during this time. These data may have been available to some but not other respondents. Further, FDA decisions on the two vaccines were not yet available, and emergency authorization for Pfizer-BioNTech and Moderna vaccines occurred, respectively, on December 11 and 18, 2020 [6, 7]—after survey completion. It likely that healthcare personnel’s opinions on vaccination will evolve over time; future surveys and ascertainties of vaccination completion are planned to capture these changes.

In summary, among 2,135 Californian healthcare personnel, we found moderate knowledge about COVID-19 vaccines, strong enthusiasm and intention for vaccination, but also certain concerns about possible side effects. Our data may help inform vaccine education campaigns for both healthcare personnel and the general public.
Figure Legends

Figure 1. Healthcare personnel’s knowledge and opinions on COVID-19 vaccines. Numbers and proportions of respondents to individual questions on aspects of COVID-19 vaccines are shown.

Figure 2. Factors influencing healthcare personnel’s opinions for and against COVID-19 vaccines. Numbers and proportions of respondents to individual questions on factors making healthcare personnel want to receive a COVID-19 vaccine (Panel A), and factors making healthcare personnel not want to receive a COVID-19 vaccine are shown (Panel B).
Funding Statement

This work was supported by a research grant from the Chan Zuckerberg Initiative.

Financial Disclosures

Vivek Jain: Funding from President’s Emergency Plan for AIDS Relief and CDC (U01GH002119), unrelated to this study.

Sarah Doernberg: Consultant, Genentech and Basilea Pharmaceutica, unrelated to this study. Funding from the NIH (UM1AI104681) for work unrelated to this study.

All authors: Research grant funding from Chan Zuckerberg Initiative for this work.

Acknowledgements

Authors gratefully acknowledge the participation of healthcare personnel in the CHART Study at UCSF Health and San Francisco General Hospital of the University of California, San Francisco, CA, and at Stanford Heath Care, Palo Alto, CA.
References


### Table 1. Demographics and work characteristics of 2,135 healthcare worker respondents

<table>
<thead>
<tr>
<th>Healthcare workers (n=2135)</th>
<th>Mean age, years (SD)</th>
<th>41.4 (10.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>396 (18.5)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1563 (73.2)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>10 (0.5)</td>
<td></td>
</tr>
<tr>
<td>Unknown/Missing</td>
<td>166 (7.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Race/Ethnicity, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>1126 (52.7)</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>26 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>218 (10.2)</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic Asian</td>
<td>426 (20.0)</td>
<td></td>
</tr>
<tr>
<td>OtherA</td>
<td>172 (8.1)</td>
<td></td>
</tr>
<tr>
<td>Unknown/MissingB</td>
<td>167 (7.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Healthcare Job (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attending/staff physician</td>
<td>353 (16.5)</td>
<td></td>
</tr>
<tr>
<td>Registered nurse</td>
<td>839 (39.3)</td>
<td></td>
</tr>
<tr>
<td>Resident/fellow physicians</td>
<td>125 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Advanced practitionerC</td>
<td>209 (9.8)</td>
<td></td>
</tr>
<tr>
<td>OtherD</td>
<td>445 (20.8)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>164 (7.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Area of Work (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intensive care units</td>
<td>246 (11.5)</td>
<td></td>
</tr>
<tr>
<td>Wards: internal medicine</td>
<td>215 (10.1)</td>
<td></td>
</tr>
<tr>
<td>Wards: other specialties</td>
<td>165 (7.7)</td>
<td></td>
</tr>
<tr>
<td>Emergency department</td>
<td>79 (3.7)</td>
<td></td>
</tr>
<tr>
<td>Acute/urgent/express care units</td>
<td>89 (4.2)</td>
<td></td>
</tr>
<tr>
<td>Work in multiple units of hospital</td>
<td>444 (20.8)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>720 (33.7)</td>
<td></td>
</tr>
<tr>
<td>Unknown/Missing</td>
<td>177 (8.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Job Categories (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct patient care with airway intubation/suctioning</td>
<td>573 (26.8)</td>
<td></td>
</tr>
<tr>
<td>Direct patient care without any airway procedures</td>
<td>1050 (49.2)</td>
<td></td>
</tr>
<tr>
<td>Indirect patient contact</td>
<td>105 (4.9)</td>
<td></td>
</tr>
<tr>
<td>Laboratory technicians/staff</td>
<td>49 (2.3)</td>
<td></td>
</tr>
<tr>
<td>Work not in setting with patients or biological samples</td>
<td>78 (3.7)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>116 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Unknown/Missing</td>
<td>164 (7.7)</td>
<td></td>
</tr>
</tbody>
</table>

A: Includes multiple races
B: Includes individuals who declined to answer
C: Physician assistant, nurse practitioner, California registered nurse anesthetist
D: Includes food services/nutritionists (11), medical or nurse assistant or technologist (44), microbiology laboratory worker (7), pathology and morgue workers (9), registration and front desk staff (13), transport (1), phlebotomy (8), physical and occupational therapy (43), radiology technician (33), respiratory/speech therapist (22), ward clerk (4), and other (250)
If a vaccine received emergency use authorization (EUA), but not formal FDA approval, how likely are you to try to receive it?

- Definitely will receive it: 235 (11%)
- Likely to receive it: 530 (25%)
- Unsure/Neutral: 679 (32%)
- Unlikely to receive it: 434 (20%)
- Definitely will not receive it: 251 (12%)
- Missing: 6 (0%)

What is the minimum level of vaccine efficacy you would like to see in a COVID-19 vaccine before agreeing to receive it?

- Near 100% efficacy: 573 (46%)
- 80% efficacy: 481 (21%)
- 60% efficacy: 448 (5%)
- 40% efficacy: 32 (1%)
- Missing: 4 (0%)

At this point, if a vaccine received formal FDA approval, how likely are you to try to receive it?

- Definitely will receive it: 742 (35%)
- Likely to receive it: 731 (34%)
- Unsure/Neutral: 463 (22%)
- Unlikely to receive it: 143 (7%)
- Definitely will not receive it: 54 (3%)
- Missing: 2 (0%)

If a vaccine was FDA approved, how early would you ideally like to receive it?

- I have a medical condition or allergy that might prevent me from being eligible: 23 (1%)
- I'd like to wait at least two months to see what the experience is: 389 (18%)
- I'd like to receive it later in the distribution process: 302 (14%)
- I'd like to receive it early, but not in the first round of people: 777 (36%)
- I'd like to be among the earliest: 541 (25%)
- Missing: 4 (0%)

Which of the following best describes your plans for influenza vaccine this winter season?

- I am not eligible to receive a flu vaccine due to a medical condition or an allergy: 8 (0%)
- I do not plan to get an influenza vaccine this season: 17 (1%)
- I have not yet decided whether to get an influenza vaccine this season: 4 (0%)
- I have not yet received influenza vaccine, but I plan to do so: 12 (1%)
- I have already received influenza vaccine this season: 2088 (98%)
- Missing: 6 (0%)
Figure 2. Factors influencing healthcare worker opinions for and against COVID-19 vaccines

A. Factors making me want to receive a vaccine

I feel I am at risk in my environment of acquiring COVID-19

- Very strong factor: 751 respondents (35%)
- Somewhat strong factor: 631 respondents (30%)
- Medium factor: 395 respondents (19%)
- Mild factor: 252 respondents (12%)
- Not a factor: 87 respondents (4%)
- Missing: 19 respondents (1%)

I have higher medical risk of having complications if I were to become infected with COVID-19

- Very strong factor: 185 respondents (9%)
- Somewhat strong factor: 209 respondents (10%)
- Medium factor: 227 respondents (11%)
- Mild factor: 410 respondents (19%)
- Not a factor: 14 respondents (1%)

I feel that I place my family, friends or contacts at some risk of COVID-19

- Very strong factor: 818 respondents (38%)
- Somewhat strong factor: 537 respondents (25%)
- Medium factor: 382 respondents (18%)
- Mild factor: 267 respondents (13%)
- Not a factor: 17 respondents (1%)

I live with individuals who I believe are at higher risk of acquiring COVID-19

- Very strong factor: 243 respondents (11%)
- Somewhat strong factor: 210 respondents (10%)
- Medium factor: 223 respondents (10%)
- Mild factor: 369 respondents (17%)
- Not a factor: 17 respondents (1%)

B. Factors making me not want to receive a vaccine

I will feel uncertain about the vaccine’s efficacy

- Very strong factor: 249 respondents (12%)
- Somewhat strong factor: 527 respondents (25%)
- Medium factor: 506 respondents (28%)
- Mild factor: 600 respondents (30%)
- Not a factor: 394 respondents (18%)
- Missing: 16 respondents (1%)

Worried about political involvement in FDA processes

- Very strong factor: 454 respondents (21%)
- Somewhat strong factor: 359 respondents (17%)
- Medium factor: 378 respondents (18%)
- Mild factor: 408 respondents (19%)
- Not a factor: 9 respondents (0%)

I have distrust of pharmaceutical companies involved in COVID-19 vaccines

- Very strong factor: 125 respondents (6%)
- Somewhat strong factor: 214 respondents (10%)
- Medium factor: 355 respondents (17%)
- Mild factor: 637 respondents (30%)
- Not a factor: 16 respondents (1%)

I don’t feel I am at high enough risk of acquiring COVID-19 illness

- Very strong factor: 31 respondents (1%)
- Somewhat strong factor: 223 respondents (10%)
- Medium factor: 442 respondents (21%)
- Mild factor: 1352 respondents (63%)
- Not a factor: 14 respondents (1%)

I would want others to have access to it before I do

- Very strong factor: 162 respondents (8%)
- Somewhat strong factor: 439 respondents (21%)
- Medium factor: 608 respondents (28%)
- Mild factor: 657 respondents (31%)
- Not a factor: 16 respondents (1%)

Worried about potential side effects

- Very strong factor: 596 respondents (28%)
- Somewhat strong factor: 442 respondents (21%)
- Medium factor: 433 respondents (20%)
- Mild factor: 450 respondents (21%)
- Not a factor: 194 respondents (9%)
- Missing: 20 respondents (1%)

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.